FDA Approves Additional Indication For Astellas’ MYCAMINE(R)

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved their Supplemental New Drug Application (sNDA) seeking approval for the use of MYCAMINE(R) (micafungin sodium) for Injection in the treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses.

More: continued here

Filed under: Infectious Diseases / Bacteria / Viruses on January 29th, 2008